EFFICACY of ESTRADIOL in PERIMENOPAUSAL DEPRESSION: So MUCH PROMISE and so FEW ANSWERS

Depression and Anxiety

Volumn 32, Issue 8, 2015, Pages 539-549

  Rubinow, David R ^a   Johnson, Sarah Lanier ^a   Schmidt, Peter J ^b   Girdler, Susan ^a   Gaynes, Bradley ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

depression; hormone; HRT; menopause; mood disorder

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; MEDROXYPROGESTERONE ACETATE; PLACEBO; RALOXIFENE; ZOLPIDEM; ESTROGEN;

ARTICLE; ASYMPTOMATIC DISEASE; BECK DEPRESSION INVENTORY; BRIEF ASSESSMENT SCALE DEPRESSION CARD; BURNAM SCALE; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CLIMACTERIUM; DEPRESSION; DRUG EFFICACY; ESTROGEN THERAPY; FEMALE; GERIATRIC DEPRESSION SCALE; HAMILTON DEPRESSION RATING SCALE; HORMONE SUBSTITUTION; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; LOW DRUG DOSE; MENOPAUSAL SYNDROME; MONTGOMERY ASBERG DEPRESSION RATING SCALE; POSITIVE AND NEGATIVE AFFECT SCHEDULE; POSTMENOPAUSE; PRIORITY JOURNAL; PROFILE OF MOOD STATES; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; WOMEN HEALTH QUESTIONNAIRE; ZUNG SELF RATING DEPRESSION SCALE; DRUG EFFECTS; MIDDLE AGED; PHYSIOLOGY; PROCEDURES;

DEPRESSION; ESTRADIOL; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; PERIMENOPAUSE;

EID: 84937971506     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.22391     Document Type: Article

References (88)

1. Colditz GA, Willett WC, Stampfer MJ, et al., Menopause and the risk of coronary heart disease in women. N Engl J Med 1987; 316 (18): 1105-1110.
2. Lett HS, Blumenthal JA, Babyak MA, et al., Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med 2004; 66 (3): 305-315.
3. Whang W, Kubzansky LD, Kawachi I, et al., Depression and risk of sudden cardiac death and coronary heart disease in women: results from the Nurses' Health Study. J Am Coll Cardiol 2009; 53 (11): 950-958.
4. Rubinow DR, Girdler SS,. Hormones, heart disease, and health: individualized medicine versus throwing the baby out with the bathwater. Depress Anxiety 2011; 28 (6): E1-E15.
5. Alyea RA, Watson CS,. Nongenomic mechanisms of physiological estrogen-mediated dopamine efflux. BMC Neurosci 2009; 10: 1-9.
6. Herbison AE, Simonian SX, Thanky NR, Bicknell RJ,. Oestrogen modulation of noradrenaline neurotransmission. Novartis Found Symp 2000; 230: 74-85; discussion 85-93.
7. Malyala A, Kelly MJ, Rønnekleiv OK,. Estrogen modulation of hypothalamic neurons: activation of multiple signaling pathways and gene expression changes. Steroids 2005; 70 (5-7): 397-406.
8. Rubinow DR, Schmidt PJ, Roca CA,. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry 1998; 44 (9): 839-850.
9. Sánchez MG, Morissette M, Di Paolo T,. Oestradiol modulation of serotonin reuptake transporter and serotonin metabolism in the brain of monkeys. J Neuroendocrinol 2013; 25 (6): 560-569.
10. Peiffer A, Lapointe B, Barden N,. Hormonal regulation of type II glucocorticoid receptor messenger ribonucleic acid in rat brain. Endocrinology 1991; 129 (4): 2166-2174.
11. Roca CA, Schmidt PJ, Altemus M, et al., Differential menstrual cycle regulation of hypothalamic-pituitary-adrenal axis in women with premenstrual syndrome and controls. J Clin Endocrinol Metab 2003; 88 (7): 3057-3063.
12. Weiser MJ, Handa RJ,. Estrogen impairs glucocorticoid dependent negative feedback on the hypothalamic-pituitary-adrenal axis via estrogen receptor alpha within the hypothalamus. Neuroscience 2009; 159 (2): 883-895.
13. Srivastava DP, Woolfrey KM, Evans PD,. Mechanisms underlying the interactions between rapid estrogenic and BDNF control of synaptic connectivity. Neuroscience 2013; 239: 17-33.
14. Calabrese F, Molteni R, Racagni G, Riva MA,. Neuronal plasticity: a link between stress and mood disorders. Psychoneuroendocrinology 2009; 34 (Suppl 1): S208-S216.
15. Castrén E, Rantamäki T,. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev Neurobiol 2010; 70 (5): 289-297.
16. Molendijk ML, Spinhoven P, Polak M, et al., Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N = 9484). Mol Psychiatry 2014; 19 (7): 791-800.
17. Arevalo MA, Azcoitia I, Garcia-Segura LM,. The neuroprotective actions of oestradiol and oestrogen receptors. Nat Rev Neurosci 2015; 16 (1): 17-29.
18. Zhang QG, Raz L, Wang R, et al., Estrogen attenuates ischemic oxidative damage via an estrogen receptor alpha-mediated inhibition of NADPH oxidase activation. J Neurosci 2009; 29 (44): 13823-13836.
19. Singer CA, Figueroa-Masot XA, Batchelor RH, Dorsa DM,. The mitogen-activated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons. J Neurosci Off J Soc Neurosci 1999; 19 (7): 2455-2463.
20. Green PS, Gridley KE, Simpkins JW,. Nuclear estrogen receptor-independent neuroprotection by estratrienes: a novel interaction with glutathione. Neuroscience 1998; 28 (1): 7-10.
21. McEwen BS, Alves SE,. Estrogen actions in the central nervous system. Endocr Rev 1999; 20 (3): 279-307.
22. Brinton RD., The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications. Trends Neurosci 2008; 31 (10): 529-537.
23. Leonard BE., Impact of inflammation on neurotransmitter changes in major depression: an insight into the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2014; 48: 261-267.
24. Berman KF, Schmidt PJ, Rubinow DR, et al., Modulation of cognition-specific cortical activity by gonadal steroids: a positron-emission tomography study in women. Proc Natl Acad Sci U S A 1997; 94 (16): 8836-8841.
25. Protopopescu X, Pan H, Altemus M, et al., Orbitofrontal cortex activity related to emotional processing changes across the menstrual cycle. Proc Natl Acad Sci U S A 2005; 102 (44): 16060-16065.
26. Dreher JC, Schmidt PJ, Kohn P, et al., Menstrual cycle phase modulates reward-related neural function in women. Proc Natl Acad Sci U S A 2007; 104 (7): 2465-2470.
27. Nestler EJ, &, Carlezon Jr WA,. The Mesolimbic Dopamine Reward Circuit in Depression. Biological Psychiatry 2006; 59 (12): 1151-1159.
28. Bekku N, Yoshimura H, Araki H,. Factors producing a menopausal depressive-like state in mice following ovariectomy. Psychopharmacology (Berl.) 2006; 187 (2): 170-180.
29. de Chaves G, Moretti M, Castro AA, et al., Effects of long-term ovariectomy on anxiety and behavioral despair in rats. Physiol Behav 2009; 97 (3-4): 420-425.
30. Lagunas N, Calmarza-Font I, Diz-Chaves Y, Garcia-Segura LM. Long-term ovariectomy enhances anxiety and depressive-like behaviors in mice submitted to chronic unpredictable stress. Horm Behav 2010; 58 (5): 786-791.
31. Bernardi M, Vergoni AV, Sandrini M, et al., Influence of ovariectomy, estradiol and progesterone on the behavior of mice in an experimental model of depression. Physiol Behav 1989; 45 (5): 1067-1068.
32. Heydarpour P, Salehi-Sadaghiani M, Javadi-Paydar M, et al., Estradiol reduces depressive-like behavior through inhibiting nitric oxide/cyclic GMP pathway in ovariectomized mice. Horm Behav 2013; 63 (2): 361-369.
33. Morgan MA, Pfaff DW,. Estrogen's effects on activity, anxiety, and fear in two mouse strains. Behav Brain Res 2002; 132 (1): 85-93.
34. Koss WA, Einat H, Schloesser RJ, et al., Estrogen effects on the forced swim test differ in two outbred rat strains. Physiol Behav 2012; 106 (2): 81-86.
35. Oyola MG, Portillo W, Reyna A, et al., Anxiolytic effects and neuroanatomical targets of estrogen receptor-β (ERβ) activation by a selective ERβ agonist in female mice. Endocrinology 2012; 153 (2): 837-846.
36. Walf AA, Rhodes ME, Frye CA,. Antidepressant effects of ERbeta-selective estrogen receptor modulators in the forced swim test. Pharmacol Biochem Behav 2004; 78 (3): 523-529.
37. Walf AA, Koonce CJ, Frye CA,. Adult female wildtype, but not oestrogen receptor beta knockout, mice have decreased depression-like behaviour during pro-oestrus and following administration of oestradiol or diarylpropionitrile. J Psychopharmacol Oxf Engl 2009; 23 (4): 442-450.
38. Zweifel JE, O'Brien WH,. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology 1997; 22 (3): 189-212.
39. Rossouw JE, Anderson GL, Prentice RL, et al., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288 (3): 321-333.
40. Manson JE, Chlebowski RT, Stefanick ML, et al., Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women's health initiative randomized trials. JAMA 2013; 310 (13): 1353-1368.
41. Murkes D, Lalitkumar PGL, Leifland K, et al., Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens/medroxyprogesterone acetate in the breasts of healthy women in vivo. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol 2012; 28 (Suppl 2): 12-15.
42. Clarkson TB., The new conundrum: do estrogens have any cardiovascular benefits? Int J Fertil Womens Med 2002; 47 (2): 61-68.
43. Williams JK, Anthony MS, Honoré EK, et al., Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol 1995; 15 (7): 827-836.
44. Guyatt GH, Oxman AD, Vist GE, et al., GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336 (7650): 924-926.
45. Viswanathan M, Ansari MT, Berkman ND, et al., Assessing the risk of bias of individual studies in systematic reviews of health care interventions. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality (US); 2008; 1-3.
46. Schiff R, Bulpitt CJ, Wesnes KA, Rajkumar C,. Short-term transdermal estradiol therapy, cognition and depressive symptoms in healthy older women. A randomised placebo controlled pilot cross-over study. Psychoneuroendocrinology 2005; 30 (4): 309-315.
47. Almeida OP, Lautenschlager NT, Vasikaran S, et al., A 20-week randomized controlled trial of estradiol replacement therapy for women aged 70 years and older: Effect on mood, cognition and quality of life. Neurobiol Aging 2006; 27 (1): 141-149.
48. Yalamanchili V, Gallagher JC,. Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause 2012; 19 (6): 697-703.
49. Pefanco MA, Kenny AM, Kaplan RF, et al., The Effect of 3-Year Treatment with 0.25 mg/day of Micronized 17β-Estradiol on Cognitive Function in Older Postmenopausal Women. J Am Geriatr Soc 2007; 55 (3): 426-431.
50. Bech P, Munk-Jensen N, Obel EB, et al., Combined versus Sequential Hormonal Replacement Therapy: A Double-Blind, Placebo-Controlled Study on Quality of Life-Related Outcome Measures. Psychother Psychosom 1998; 67 (4-5): 259-265.
51. Haines CJ, Yim SF, Chung TKH, et al., A prospective, randomized, placebo-controlled study of the dose effect of oral oestradiol on menopausal symptoms, psychological well being, and quality of life in postmenopausal Chinese women. Maturitas 2003; 44 (3): 207-214.
52. Pearce J, Hawton K, Blake F, et al., Psychological effects of continuation versus discontinuation of hormone replacement therapy by estrogen implants: A placebo-controlled study. J Psychosom Res 1997; 42 (2): 177-186.
53. Gambacciani M, Ciaponi M, Cappagli B, et al., Effects of low-dose, continuous combined estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal women. Maturitas 2003; 44 (2): 157-163.
54. Strickler R, Stovall DW, Merritt D, et al., Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo-controlled randomized trial. Obstet Gynecol 2000; 96 (3): 359-365.
55. Nielsen TF, Ravn P, Pitkin J, Christiansen C,. Pulsed estrogen therapy improves postmenopausal quality of life: a 2-year placebo-controlled study. Maturitas 2006; 53 (2): 184-190.
56. Girdler SS, O'Briant C, Steege J, et al., A comparison of the effect of estrogen with or without progesterone on mood and physical symptoms in postmenopausal women. J Womens Health Gend Based Med 1999; 8 (5): 637-646.
57. Demetrio FN, Renno J Jr, Gianfaldoni A, et al., Effect of estrogen replacement therapy on symptoms of depression and anxiety in non-depressive menopausal women. Arch Womens Ment Health 2011; 14 (6): 479-486.
58. Beck AT, Steer RA, Brown GK,. Manual for Beck Depression Inventory II (BDI-II). San Antonio, TX: Psychology Corporation; 1996.
59. Karşidaʇ Ç, Karageyim Karşidaʇ AY, Esim Büyükbayrak E, et al., Comparison of effects of two different hormone therapies on mood in symptomatic postmenopausal women. Archives of Neuropsychiatry 2012; 49 (1): 39-43.
60. Hlatky MA, Boothroyd D, Vittinghoff E, et al., Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: Results from the heart and estrogen/progestin replacement study (hers) trial. JAMA 2002; 287 (5): 591-597.
61. Hays J, Ockene JK, Brunner RL, et al., Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003; 348 (19): 1839-1854.
62. Welton AJ, Vickers MR, Kim J, et al., Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ 2008; 337: a1190.
63. Burnam MA, Wells KB, Leake B, Landsverk J,. Development of a brief screening instrument for detecting depressive disorders. Med Care 1988; 26 (8): 775-789.
64. Resnick SM, Espeland MA, An Y, et al., Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy. J Clin Endocrinol Metab 2009; 94 (11): 4152-4161.
65. Resnick SM, Maki PM, Rapp SR, et al., Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab 2006; 91 (5): 1802-1810.
66. Khoo SK, Coglan M, Battistutta D, et al., Hormonal treatment and psychological function during the menopausal transition: an evaluation of the effects of conjugated estrogens/cyclic medroxyprogesterone acetate. Climacteric 1998; 1 (1): 55-62.
67. Schmidt PJ, Nieman L, Danaceau MA, et al., Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 2000; 183 (2): 414-420.
68. de Novaes Soares C, Almeida OP, Joffe H, Cohen LS,. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001; 58 (6): 529-534.
69. Morrison MF, Kallan MJ, Ten Have T, et al., Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial. Biol Psychiatry 2004; 55 (4): 406-412.
70. Rudolph I, Palombo-Kinne E, Kirsch B, et al., Influence of a continuous combined HRT (2 mg estradiol valerate and 2 mg dienogest) on postmenopausal depression. Climacteric J Int Menopause Soc 2004; 7 (3): 301-311.
71. Joffe H, Petrillo LF, Koukopoulos A, et al., Increased estradiol and improved sleep, but not hot flashes, predict enhanced mood during the menopausal transition. J Clin Endocrinol Metab 2011; 96 (7): E1044-E1054.
72. Conklin W,. Climacteric insanity. Am J Med Sci 1971; 62 (124): 365-373.
73. Werner AA, Johns GA, Hoctor EF, et al., Involutional melancholia: probable etiology and treatment. J Am Med Assoc 1934; 103 (1): 13-16.
74. Santen RJ, Allred DC, Ardoin SP, et al., Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010; 95 (7 Suppl 1): S1-S66.
75. Yaffe K, Sawaya G, Lieberburg I, Grady D,. Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia. JAMA 1998; 279 (9): 688-695.
76. Barrett-Connor E., Hormones and heart disease in women: the timing hypothesis. Am J Epidemiol 2007; 166 (5): 506-510.
77. Prentice RL, Manson JE, Langer RD, et al., Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 2009; 170 (1): 12-23.
78. Rossouw JE, Prentice RL, Manson JE, et al., Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297 (13): 1465-1477.
79. Clarkson TB., Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause N Y N 2007; 14 (3 Pt 1): 373-384.
80. Mikkola TS, and, Clarkson TB,. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002; 53 (3): 605-619.
81. Suzuki S, Brown CM, Dela Cruz CD, et al., Timing of estrogen therapy after ovariectomy dictates the efficacy of its neuroprotective and antiinflammatory actions. Proc Natl Acad Sci U S A 2007; 104 (14): 6013-6018.
82. Zhang Q, Han D, Wang R, et al., C terminus of Hsc70-interacting protein (CHIP)-mediated degradation of hippocampal estrogen receptor-alpha and the critical period hypothesis of estrogen neuroprotection. Proc Natl Acad Sci U S A 2011; 108 (35): E617-E624.
83. Harlow SD, Gass M, Hall JE, et al., Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Climacteric J Int Menopause Soc 2012; 15 (2): 105-114.
84. Beral V, and Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362 (9382): 419-427.
85. Björn I, Sundström-Poromaa I, Bixo M, et al., Increase of estrogen dose deteriorates mood during progestin phase in sequential hormonal therapy. J Clin Endocrinol Metab 2003; 88 (5): 2026-2030.
86. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, et al., Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997; 17 (11): 3071-3078.
87. Avis NE, Brambilla D, McKinlay SM, Vass K,. A longitudinal analysis of the association between menopause and depression. Results from the Massachusetts Women's Health Study. Ann Epidemiol 1994; 4 (3): 214-220.
88. Bromberger JT, Kravitz HM, Chang YF, et al., Major depression during and after the menopausal transition: Study of Women's Health Across the Nation (SWAN). Psychol Med 2011; 41 (9): 1879-1888.